Article Text

Download PDFPDF
Impulse control disorders in Parkinson’s disease: a hard-turning point
  1. Juan Carlos Martinez-Castrillo
  1. Movement Disorders and Neurodegenerative Unit, Service of Neurology, IRYCIS. Hospital Ramon y Cajal, Madrid 28034, Spain
  1. Correspondence to Dr Juan Carlos Martinez-Castrillo, Movement Disorders and Neurodegenerative Unit, Service of Neurology, IRYCIS. Hospital Ramon y Cajal, Madrid 28034, Spain; jcmcastrillo{at}gmail.com

Statistics from Altmetric.com

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

First trial on management of ICD in Parkinson disease and new risk factors

Impulse control disorders (ICD) are one of the main concerns when dealing with Parkinson’s disease (PD) treatment. Many movement disorder specialists have witnessed dramatic histories of ruin, relationship problems, litigation and, more commonly, distress and grief of patients with PD and caregivers. The frequency of ICD in PD is highly variable (15%–40%) depending on certain features of the population, particularly younger age and male sex.1 2 Dopamine agonists, mainly D3 agonists (pramipexole, ropinirole and rotigotine), are the main risk factor. This is not a dose-dependent effect; however, higher doses entail a greater risk. Dopamine agonists with a short half-life may also carry a higher risk, as rotigotine patch and prolonged …

View Full Text

Footnotes

  • Contributors JCMC is the sole author of this paper, which is an original contribution.

  • Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

  • Competing interests None declared.

  • Patient consent Not required.

  • Provenance and peer review Commissioned; internally peer reviewed.

Linked Articles